Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Neonc Technologies Holdings Inc's Competitiveness

Name: Neonc Technologies Holdings Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Neonc Technologies Holdings Inc (NTHI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/NTHI/competitors                    

                        https://api.csimarket.com/api/v1/companies/NTHI/relationships                    

                        https://api.csimarket.com/api/v1/companies/NTHI/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Neonc Technologies Holdings Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Neonc Technologies Holdings Inc	-	-	-	Yes
High-Confidence Competitors (2)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

NTHI Stock Performance relative to its Competitors

NTHI Competitors (weighted) Percent change over the selected range

Neonc Technologies Holdings Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(2 of 2)

Similar-Size
(1 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Neonc Technologies Holdings Inc	-63.90 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (2)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Neonc Technologies Holdings Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

NTHI Stock Performance relative to High-Confidence Competitors

NTHI High-Confidence Competitors (equal-weighted, 3) Percent change over the selected range

NTHI Stock Performance relative to Similar-Size Competitors

NTHI Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Neonc Technologies Holdings Inc's Comment on Competition and Industry Peers

The competitive landscape for NEO100 and NEO212 encompasses the global central nervous system (CNS) treatment market and the brain tumor drug market. The CNS market covers indications such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and schizophrenia, with established companies including Pfizer, Roche, and Novartis. The brain tumor drug market addresses various tumor types, including glioblastoma multiforme, meningioma, and astrocytoma, and involves competition among pharmaceutical companies, medical device manufacturers, and radiation therapy providers. Key factors in competition include clinical effectiveness, regulatory approvals, market access, pricing, marketing, development of targeted therapies, immunotherapeutic strategies, clinical trial outcomes, and orphan drug designations. Patient advocacy organizations also play a role in influencing drug development.

Competitor data is not yet available for Neonc Technologies Holdings Inc.

Neonc Technologies Holdings Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Roche	Named by the company	85%	2022 to 2026	3
Novartis	Named by the company	85%	2022 to 2026	3
Pfizer	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Neonc Technologies Holdings Inc's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.